Versant Ventures, a global healthcare venture capital firm, launched its third biotech incubator, Highline Therapeutics.
The firm also promoted Carlo Rizzuto as Venture Partner to manage its newly established New York base. Rizzuto, who joined Versant in 2012 as Operating Principal and played key roles in a number of investments including GenSight, Piqur, Anokion and Mosaic, will lead investments in innovative biotech startups as part of Versant’s strategy to expand its operations to New York and intensify investment activities in the broader Northeast. Since mid-2014, he has led the effort to establish Highline Therapeutics.
Based in Highline’s office in Manhattan, he will work with Versant’s team of investment professionals and entrepreneurs to establish a broad portfolio of startups. The firm also added Cameron Pitt as Associate as part of the New York based team.
Led by Brad Bolzon, Managing Director, Versant Ventures is a healthcare investment firm that invests across the healthcare sector and at all stages of company development. It has $1.9 billion under management and offices in North America and Europe. In addition to Highline, Versant’s network of regional discovery engines includes Blueline Bioscience in Toronto, and Inception Sciences in San Diego, Vancouver and Montreal.
FinSMEs
24/08/2015